Best Psychedelic Therapy for PTSD: What the Evidence Shows

What Is the Most Effective Psychedelic Therapy for PTSD? At a Glance

Across the three most-studied options, reported outcomes land in a broadly similar range. What most separates them is whether you can actually get them.

MDMA-assisted therapy is the only option with completed Phase 3 trials for PTSD. In the most recent, 71% of participants no longer met criteria for PTSD, against 48% who received therapy plus an inactive capsule (Mitchell et al., 2023).¹ It is not approved and remains available only through clinical trials.

Ketamine therapy reports outcomes in the same range and is the one you can access today. In Mindbloom's published study of its at-home program, 84.6% of patients saw clinically meaningful improvement and 76.7% responded over six sessions (Parks et al., 2026).³

Psilocybin has encouraging early results in small studies. A Phase 2 trial of 22 people with PTSD reported a 62% drop in symptom scores by week 12, with 77% meeting the study's response threshold (McGowan et al., 2026).⁴

These studies used different raters, different thresholds, and different follow-up periods, so the percentages are not directly interchangeable. The table below compares all six options, and each is examined in more detail in the sections that follow.

How the Options Compare

_{Response and remission thresholds differ between these studies, so the percentages above are not directly comparable. The next section explains what to watch for.}

Official guidance is evolving. The VA/DoD Clinical Practice Guideline for PTSD, last updated in 2023, does not recommend psychedelics or ketamine as standard standalone treatments, and trauma-focused psychotherapy and certain SSRIs remain first-line.⁵ Federal policy has since moved faster than the guidelines: an executive order in April 2026 directed the FDA to prioritize review of psychedelic treatments and the DEA to ease research restrictions, and the FDA issued priority vouchers to three programs, one of them for PTSD.⁶ The order does not legalize any of these compounds.

How to Read the Percentages You'll See

You will run into a lot of numbers while researching this, on clinic websites, in news coverage, and in the studies themselves. They are rarely measuring the same thing. Three questions tell you what any of them is worth.

Is it measuring symptom change, or how many people hit a benchmark? These are different questions, and the same data can answer them very differently. In a 2026 study of 346 people receiving psilocybin services, average symptom scores fell 26%, while the share of people scoring above the clinical threshold fell 65% (Korthuis et al., 2026).⁷ Both are true. One describes how far symptoms moved, the other describes how many people crossed a line.

Where is the benchmark set? Words like response and remission are thresholds, and each study picks its own. Mindbloom's PTSD analysis counted a response as a drop of 10 points or more on the PCL-5.³ The psilocybin trial above required 15 points on a clinician-rated scale, a harder bar to clear.⁴ Two studies can report the same response rate and not mean the same thing by it.

How was the study run? Ask whether there was a comparison group. MDMA's Phase 3 trial reported 71% for the MDMA group and 48% for the group given the same therapy with an inactive capsule, and the gap between them is what the drug added.¹ Studies without a comparison group, including the at-home ketamine data, can only tell you how their own patients did. Then ask whether people were tracked over time or asked afterward to recall how they felt. One ibogaine program has been measured both ways, and the recall version produced an effect roughly nine times larger.⁸⁻⁹

A percentage on its own tells you very little. These three questions turn it back into information.

MDMA-Assisted Therapy for PTSD: Strong Results, Available Only in Trials

MDMA-assisted therapy has produced strong results in two large Phase 3 trials that agreed with each other. It is not FDA-approved for PTSD and remains unavailable outside of clinical trials.

What the Trials Show

In the first Phase 3 trial, 67% of participants no longer met criteria for PTSD after treatment, against 32% of those who received the same therapy with an inactive capsule (Mitchell et al., 2021).¹⁰ The second reported 71% against 48% (Mitchell et al., 2023).¹ Both followed earlier, smaller randomized studies pointing the same direction.

Measured by symptom severity rather than diagnosis, scores in the MDMA group fell by roughly 55% in the first trial.¹⁰ In the second, they fell by roughly 60%.¹ These were not mild cases. Participants had lived with PTSD for an average of more than 14 years.¹⁰

What the trials tested is worth understanding, because it is not a prescription. Each participant received roughly 42 hours of structured treatment: three preparatory sessions, three eight-hour dosing sessions, and nine integration sessions afterward, with two therapists present throughout. Three of those days involved the drug. The rest was therapy.

Two 2026 reviews that pooled these trials rated the overall certainty of the evidence as low or very low, citing small sample sizes and the difficulty of keeping participants unaware of which treatment they received.¹¹⁻¹² That is a normal position for a treatment at this stage rather than a verdict against it.

Where MDMA Therapy Stands With the FDA

The FDA declined to approve MDMA-assisted therapy on August 9, 2024, issuing a Complete Response Letter and requesting an additional Phase 3 trial.² A new application was submitted in 2026, but no approval decision has been announced and no date has been set.

Until that changes, MDMA remains a Schedule I substance. The only legal way to receive MDMA-assisted therapy in the United States is to enroll in an active clinical trial, which you can search for at ClinicalTrials.gov.

Ketamine Therapy for PTSD: The Option You Can Access Today

Ketamine is the only psychedelic-style therapy legally available at scale in the United States. It is an FDA-approved anesthetic that clinicians prescribe off-label for mental health conditions, which is why ketamine therapy for PTSD does not require a clinical trial to access. It is also the only one of these options with peer-reviewed PTSD outcomes from an at-home setting. Mindbloom's published study of its telehealth program is the first at-home ketamine data for PTSD, where every prior ketamine-for-PTSD trial was a small in-clinic IV study (Parks et al., 2026).

How Ketamine Is Given for PTSD

There are three main routes, and they differ in setting, cost, and supervision.

• Intravenous ketamine is given in a clinic, usually as a series of infusions over two to three weeks. This is the route used in most of the published PTSD trials.
• Esketamine (Spravato) is a nasal spray approved by the FDA for treatment-resistant depression, not for PTSD. It must be administered in a certified healthcare setting with monitoring afterward.
• At-home sublingual or subcutaneous ketamine is prescribed through telehealth and self-administered at home with remote clinician supervision and a required support person present.

What the Research Shows

In Mindbloom's published study of its at-home subcutaneous program, 623 patients began treatment with baseline PTSD scores. Among those completing six sessions, 84.6% saw clinically meaningful improvement, 76.7% responded, and 56.7% reached remission, defined as a 10-point or greater drop with a final score below the clinical threshold (Parks et al., 2026).³ Symptoms fell about 40% overall.

Relief came early for many. By the second session, roughly two weeks in, 56.4% had already responded.³

Those results are consistent with earlier in-clinic research. A randomized trial of repeated intravenous ketamine reported a 67% response rate against 20% for an active control (Feder et al., 2021).¹³

Results across the randomized ketamine trials have been mixed, and the evidence base for PTSD specifically is still developing. What distinguishes the at-home data is scale and setting: it reflects several hundred people treated in ordinary conditions rather than a screened trial population.

In the same Mindbloom analysis, side effects were infrequent and generally mild, reported by 2.8% to 3.2% of patients at each check-in, with serious adverse events in 0.08% of cases.³

For veterans specifically, who carry a higher PTSD burden than the general population, we cover treatment considerations in more detail in our guide to ketamine therapy for veterans with PTSD.

Psilocybin-Assisted Therapy for PTSD: Encouraging Early Results

Psilocybin has produced strong results in the PTSD studies published so far, but those studies are small, and no randomized controlled trial in people diagnosed with PTSD has been published yet.

What the Studies Show

The largest published trial gave a single 25 mg dose to 22 people with PTSD, alongside preparation and integration sessions. Symptom scores fell about 62% by week 12, and 77% met the study's response threshold, which required a 15-point drop on a clinician-rated scale (McGowan et al., 2026).⁴

A separate trial treated 12 military veterans with treatment-resistant PTSD using two doses several weeks apart. Symptom scores fell about 69%, and 9 of the 12 participants both responded and reached remission (Armstrong et al., 2026).¹⁴

Both results are encouraging, and both come from very small groups. Twenty-two people and twelve people are enough to justify larger trials, not enough to settle how well a treatment works. A Phase 2/3 program in PTSD is now recruiting.

Where Psilocybin Stands Legally

Psilocybin is a Schedule I substance under federal law. Oregon and Colorado have created state-regulated programs for supervised adult use, but these are not medical treatment programs and are not authorized for treating PTSD specifically.

Outside those state programs, the only legal way to receive psilocybin-assisted therapy is through a clinical trial.

Why the Therapy Around the Dose Matters as Much as the Drug

Across this research, one pattern is consistent: the strongest results come from a medicine paired with structured psychological work. The therapy is not an add-on. It plays an integral role in the outcomes these trials report.

The Phase 3 MDMA trials show this clearly. Both groups received the same 42-hour therapy protocol, and only one received MDMA. The MDMA group did significantly better.¹ The comparison group also improved, reaching roughly 57% of the MDMA group's improvement in the first trial¹⁰ and 62% in the second.¹

The psilocybin research points the same way. In the veterans trial, symptom scores had already fallen from 39.7 to 33.3 during eight hours of preparatory therapy, before anyone received a dose.¹⁴

The authors of the second MDMA trial addressed this directly, noting that the comparison-group result "could suggest the standalone value of the manualized inner-directed therapy" developed for use alongside the drug.¹

The practical implication is that these are protocols rather than prescriptions, so how a program is built matters as much as which compound it uses. Providers differ here. Mindbloom builds its at-home care around this, offering a dedicated PTSD program that structures preparation, intention setting, and integration around the medicine rather than treating them as add-ons.

Is Psychedelic Therapy for PTSD Safe?

In research settings these treatments are delivered under supervision, with screening beforehand and monitoring during and after the session. That structure is part of why the safety record in trials has been reasonably good, and it is also why the same compounds carry different risks outside of it.

Who These Treatments Are Not For

Across the MDMA, psilocybin, and ketamine studies, researchers screened out similar groups of people. Common exclusions include:

• A personal or family history of schizophrenia, bipolar disorder, or other psychotic conditions
• Significant or unstable cardiovascular disease, including uncontrolled high blood pressure
• Current active suicidal ideation
• Pregnancy

Any legitimate provider or trial will screen for these before starting treatment. A program that does not ask is a warning sign.

How to Decide Which Option Fits

Most of the research debate resolves into a few practical situations.

"I'm struggling now and want something with published evidence that I can actually start."Ketamine therapy is the option that fits. It is available by prescription today, has published PTSD outcomes, and can begin within days rather than after a trial screening process.

"I want the treatment with the strongest randomized results, and I'm willing to wait."That is MDMA-assisted therapy, and the only legal route is a clinical trial. Enrollment is competitive and sites are limited, so this works best if you are not in crisis and are able to travel.

"I've read about psilocybin and want to try it for PTSD."A clinical trial is the only legal path. The Oregon and Colorado programs are not PTSD treatment and were not designed for it.

"Standard treatments haven't worked for me."That is the situation most of this research studied. Participants in the MDMA trials had lived with PTSD for an average of more than 14 years, and most had tried other treatments first.¹⁰ We walk through the next steps in our guide to what to try for PTSD when therapy and medication are not enough.

"I'm a veteran."Veterans carry a higher PTSD burden than the general population and have additional trial pathways through the VA. We go deeper on the options in our guide to ketamine therapy for veterans with PTSD.